Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Emerg Drugs. 2009 Sep;14(3):395-410. doi: 10.1517/14728210903153862.

Developments in the treatment of visceral leishmaniasis.

Author information

1
23A Oval Road, NW1 7EA London, UK. margrietdenboer@gmail.com

Abstract

BACKGROUND:

Visceral leishmaniasis (VL) is one of the most neglected parasitic diseases causing large scale mortality and morbidity among the poorest of the poor in the Indian subcontinent and Africa.

OBJECTIVE:

This review aims to describe the potential and the (lack of) current impact of newly developed treatments on the control of VL. It describes how the problem of an empty research pipeline is addressed, and discusses the emerging threat of incurable HIV/VL coinfection.

METHODS:

The literature was searched for drugs used in VL.

CONCLUSION:

Research and development of VL drugs has received a financial boost but no new drugs are expected in the next 5 years. Only three new and highly effective treatments have been licensed in the past 10 years. These remain, however, largely inaccessible as VL control programs in the developing world are lacking. This is deserving of immediate and urgent attention, especially in the context of the rapidly expanding HIV/VL coinfection.

PMID:
19708817
DOI:
10.1517/14728210903153862
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center